Research & Development

Emerging Innovations Propel CAR-T Therapy to 2033 Market Expansion
Research & Development Emerging Innovations Propel CAR-T Therapy to 2033 Market Expansion

The landscape of Chimeric Antigen Receptor T-cell (CAR-T) therapies is witnessing rapid evolution as emerging companies introduce innovative solutions to overcome existing challenges. These therapies, which involve genetically engineering a patient’s T cells to target cancer cells, have shown

Can AI and Supercomputing Revolutionize Drug Discovery?
Research & Development Can AI and Supercomputing Revolutionize Drug Discovery?

In recent years, the intersection of advanced computing and biological research has elevated the prospects of drug discovery to unprecedented heights. The seamless integration of AI, machine learning, and supercomputing promises a paradigmatic shift from traditional empiricism to computational

Can NK Cell Therapy Revolutionize Autoimmune Disease Treatment?
Research & Development Can NK Cell Therapy Revolutionize Autoimmune Disease Treatment?

Natural Killer (NK) cell therapy, once a promising beacon for cancer treatment, is now being repositioned as a potential game-changer in the management of autoimmune diseases. Biotech companies, like Artiva Biotherapeutics, are shifting their focus to explore the untapped potential of NK cell

Microfluidic Chip Revolutionizes CAR T-Cell Manufacturing Efficiency
Research & Development Microfluidic Chip Revolutionizes CAR T-Cell Manufacturing Efficiency

The recent breakthrough in CAR T-cell manufacturing is nothing short of revolutionary. Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) at the Singapore-MIT Alliance for Research and Technology (SMART), in collaboration

Can GTB-3650 Revolutionize CD33+ Leukemia Treatment with NK Cell Engagers?
Research & Development Can GTB-3650 Revolutionize CD33+ Leukemia Treatment with NK Cell Engagers?

In a significant achievement for GT Biopharma, Inc., the FDA has granted clearance for the company's Investigational New Drug (IND) application for GTB-3650, a novel NK cell engager aimed at treating CD33+ leukemia. This regulatory milestone allows the clinical-stage immuno-oncology company to

Can Diverse Clinical Trials Restore Trust in Minority Communities?
Research & Development Can Diverse Clinical Trials Restore Trust in Minority Communities?

The healthcare system's history of unethical practices and ongoing issues has fostered a deep mistrust among minority communities. This mistrust affects everything from routine healthcare appointments to participation in clinical trials. Despite significant efforts to increase diversity, enrollment

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later